Ethnobotanical significance of medicinal plants: Beta‐amyloid and tau aggregation inhibitors against Alzheimer's disease

• Published in: Journal of biochemical and molecular toxicology 2023-06, Vol.37 (6), p.e23339-n/a
• Main Authors: Ganapathy, A. Anand, Haripriya, Vijayakumari M., Acharya, Niyati, Somappa, Sasidhar B., Kumaran, Alaganandam
• Format: Article
• Language: English
• Subjects: Aged; Alzheimer Disease - metabolism; Alzheimer's disease; Amyloid beta-Peptides - metabolism; beta‐amyloid; Carotenoids; Cholinesterase; Cholinesterase Inhibitors - therapeutic use; Clinical trials; Cognitive ability; Dementia disorders; Drug development; Ethnobotany; Failure rates; Flavonoids; Genetics; Glycosides; Health services; Herbal medicine; Humans; Inflammation; Inhibitors; Medicinal plants; Neurodegenerative diseases; Neurofibrillary tangles; phytochemistry; Plants, Medicinal - metabolism; Senile plaques; Side effects; Signs and symptoms; tau; Tau protein; tau Proteins - metabolism
• ISSN: 1095-6670; 1099-0461
• DOI: 10.1002/jbt.23339

Among the various neurodegenerative disorders, Alzheimer's disease (AD) is identified as one of primary causes of dementia in the elderly, which progresses slowly leading to cognitive decline and ability to function independently. Although various pathological mechanisms have been proposed, the exact mechanism is not yet elucidated. Numerous processes such as old age, mitochondrial dysfunction, and genetics lead to the aggregation of beta‐amyloid (Aβ) as amyloid plaques and tau proteins as neurofibrillary tangles in the neurons leading to their death and destruction, finally leading to AD. The current treatment measures can only temporarily improve the symptoms, slowing cognitive decline without any effect on AD pathology for better therapeutic effect. Furthermore, the high failure rates of a number of drugs during clinical trials due to their side effects has led the researchers to focus on alternative sources for drug development. As natural ingredients were considered the primary line of treatment in the olden days, and as several medicinal plant products are also proven as effective AD targets, it will be wise to investigate those with significant ethnobotanical value as potential neuroprotectives, nootropics or memory boosters. Throughout the study, propanoids, glycosides, iridoids, carotenoids and flavonoids that show potential anti‐inflammatory, antioxidant, and anti‐cholinesterase were also found to be inhibitors of Aβ and tau aggregation, where Saikosaponin C, Fisetin, and Morin can act as dual inhibitors. The review provides an insight in the need for proper and complete scientific evaluation of these ethnobotanically useful medicinal plants to be identified as potential leads in AD therapy.